Request Demo

Last update 02 Apr 2026

Sodium Thiosulfate

Last update 02 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Monosulfanemonosulfonic acid, Sodium Aurotiosulfate, Sodium thiosulfate (USP)

+ [12]

Target-

Action

donors

Mechanism

Sulfur atom donors

Therapeutic Areas

Otorhinolaryngologic DiseasesOther DiseasesNervous System Diseases

Active Indication

Hearing LossOtotoxicityDisinfectants+ [2]

Inactive Indication

CalciphylaxisEye Diseases

Originator Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Active Organization

Norgine BV

Fennec Pharmaceuticals, Inc.

Kenei Pharmaceutical Co Ltd.

+ [4]

Inactive Organization

Byondis BV

Decibel Therapeutics, Inc.

U.S. Army War College

License Organization

Norgine BV

Fennec Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (11 May 1984),

Poisoning

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Fast Track (United States)

Structure/Sequence

Molecular FormulaH12Na2O8S2

InChIKeyJIWXHKJJHDWKGC-UHFFFAOYSA-N

CAS Registry10102-17-7

Clinical Trials associated with Sodium Thiosulfate

NCT07407582

/ Not yet recruitingPhase 1/2IIT

Phase I/II Open Label Trial of Intravenous Sodium Thiosulfate (Pedmark®) as Otoprotectant in Adults Receiving Cisplatin Chemotherapy (STOP-CIS)

The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is approved for use in the pediatric and young adult population. However, information in adult patients is limited. As most cisplatin is administered in the adult population, this investigation would be of benefit.

Start Date30 Apr 2026

Sponsor / Collaborator

University of Arizona

[+1]

NCT07218913

/ RecruitingPhase 1IIT

Phase 1 Trial of Pedmark in Men Receiving Cisplatin for Metastatic Germ Cell Tumor

This phase I trial evaluates whether adding Pedmark to standard of care cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with stage II-III testicular germ cell tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Cisplatin-induced ototoxicity remains a major concern in adult patients with germ cell tumors as nearly four out of five patients develop hearing loss after treatment. Cisplatin is thought to cause ear damage by the production of chemically reactive molecules called reactive oxygen species. These molecules can cause damage when their levels get too high. Pedmark may reduce the negative side effects of cisplatin by neutralizing these reactive molecules. Pedmark has been approved for reducing the risk of cisplatin-induced ototoxicity in pediatric patients and older patients with solid tumors that haven't spread to other parts of the body. Adding Pedmark to cisplatin-based chemotherapy treatment may reduce ototoxicity in adult men with stage I-III testicular metastatic germ cell tumors.

Start Date04 Mar 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07228429

/ RecruitingNot ApplicableIIT

Quantification of Calcinosis Cutis Disease Burden in Patients With Systemic Sclerosis Using Computed Tomography Images

The main purpose of this study is to develop sensitive radiographic measurement techniques that can be used as outcome measures along with patient-reported outcome instruments in clinical trials of calcinosis cutis treatments, and potentially be used to assess disease course and treatment response in clinical practice. The goal is to test the performance of the software.

Start Date14 Oct 2025

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Sodium Thiosulfate

100 Translational Medicine associated with Sodium Thiosulfate

100 Patents (Medical) associated with Sodium Thiosulfate

2,636

Literatures (Medical) associated with Sodium Thiosulfate

31 Dec 2026·ANNALS OF MEDICINE

Advances in the clinical applications of sodium thiosulphate

Review

Author: Ke, Jingjing ; Zang, Hualong ; Deng, Yiting ; Liu, Yang ; Wang, Ping

BACKGROUND:

Sodium thiosulphate (STS) is a clinically approved pharmaceutical agent known for its antioxidant and sulphide-releasing properties. Currently, it is commonly employed in the detoxification treatment of various chemical intoxications, including cyanide, arsenic, and lead poisoning. In recent years, research into the clinical applications of STS has advanced rapidly, resulting in numerous significant breakthroughs. However, awareness and adoption of these developments remain limited among clinical practitioners.

DISCUSSION:

In addition to its research progress in the treatment of cyanide poisoning, STS has also demonstrated protective effects against chemotherapeutic drug-induced ototoxicity and nephrotoxicity, as well as in conditions such as vascular calcification and uraemic pruritus. Furthermore, STS has been shown to exert protective effects on multiple organs, including the heart, brain, and kidneys, by mitigating ischaemia-reperfusion injury. There is also evidence suggesting that STS may offer protection in diseases such as preeclampsia and hypertensive renal injury. However, these studies exhibit considerable variability in terms of STS administration strategies.

CONCLUSIONS:

This paper provides a comprehensive review of current preclinical and clinical studies on STS, with the aim of highlighting its potential therapeutic applications in chemical intoxications, cancer treatment, vascular calcification, uraemic pruritus, and other related pathological conditions. Owing to its multiple biological protective effects and a favourable safety profile, STS is anticipated to receive growing recognition among the medical community, which may pave the way for the exploration of novel clinical indications and contribute meaningfully to public health.

01 Mar 2026·OTOLOGY & NEUROTOLOGY

Impact of pH on Intratympanic Sodium Thiosulfate-hyaluronan Gel in Preventing Cisplatin-induced Ototoxicity

Article

Author: Laurell, Göran ; Fransson, Anette ; Videhult Pierre, Pernilla

Hypothesis::

The pH of an intratympanic gel influences the level of protection against the ototoxic effects of systemic cisplatin.

Background::

Nucleophiles reduce cisplatin-induced ototoxicity by chemically inactivating cisplatin and counteracting oxidative stress. pH is a factor influencing cisplatin’s reactivity. Here, intratympanic administration of a hyaluronan-based gel containing the nucleophile sodium thiosulfate (STS) was used to investigate the role of pH in otoprotection.

Methods::

Guinea pigs (n=32) received a unilateral transtympanic injection of a hyaluronan-based gel (0.10 to 0.15 mL) with either STS at pH 6.5 or pH 8.0, or NaCl at pH 6.5 or pH 8.0. The contralateral ear served as control. After 30 minutes, cisplatin (8 mg/kg b.w., i.v.) was administered. Cochleae were harvested 4 days later for hair cell quantification.

Results::

Mean percentage of outer hair cell (OHC) loss per mm in the region ≤10 mm from the round window had a median absolute intraindividual difference of 6.0% (quartiles 1 and 2: 3.8% to 11%; P =0.012; n=8) in group STS pH 6.5 and 5.8% (1.8% to 18%; P =0.046; n=6) in group STS pH 8.0, favoring the gel-treated ear. The corresponding numbers in the NaCl groups were −0.2% (−2.2 to 8.7%; P =1.000; n=8) in group NaCl pH 6.5 and 3.3% (−8.1% to 22%; P =0.237; n=7) in group NaCl pH 8.0. The difference between nontreated and gel-treated ears did not differ significantly between the 2 STS groups.

Conclusion::

STS in a hyaluronan-based gel reduced OHC loss equally well at both pH levels, while NaCl was ineffective.

01 Mar 2026·JOURNAL OF ENVIRONMENTAL MANAGEMENT

Effects of tillage practices on aggregate-associated soil organic carbon fractions and maize yield

Article

Author: Chen, Liyu ; Cheng, Yuchen ; Zhao, Kun ; Wei, Xiuqing ; Ye, Jun ; Di, Yejia ; Li, Juan ; Tian, Lei ; Wei, Shuli ; Li, Zhenwei ; Lu, Zhanyuan

Tillage practices can disrupt soil surface, creating loose, erodible soil layers. This significantly impacts soil organic carbon (SOC) fractions, including microbial biomass carbon (MBC), dissolved organic carbon (DOC), particulate organic carbon (POC), readily oxidizable organic carbon (ROC), and heavy fraction organic carbon (HFOC). SOC fractions may depend on soil aggregate size. However, the variation patterns of SOC fractions under different soil aggregate sizes and tillage practices remain unclear. The objectives of this study were to assess the impact of tillage practices on SOC fractions (MBC, DOC, POC, ROC, and HFOC) within soil aggregates and to quantify the relationship between aggregate size and these SOC fractions. Seven treatment combinations were selected: two conventional tillage practices of rotary tillage (RTS) and plow-tillage (PTS) with 100% harvest maize stover mulching, and five conservation tillage practices of subsoiling+100% mulching (STS), no-tillage+30% (NTS1) and 100% (NTS2) mulching, and no-tillage & ridging+30% (NTSR1) and 60% (NTSR2) mulching. Results showed that tillage practices significantly impacted SOC fractions and maize yield (P < 0.05). Specifically, conservation tillage outperformed conventional tillage in enhancing SOC and its labile labile organic carbon (LOC, including MBC, DOC, POC, ROC) by retaining crop residues, increasing carbon inputs, and reducing mechanical disturbance. Mineral-associated organic carbon (MAOC) and heavy fraction organic carbon (HFOC) are classified as stable SOC fractions, and conservation tillage also promoted the accumulation of stable SOC. NTS2 was optimal for SOC accumulation in the 0-20 cm soil layer. STS promoted root carbon input in the 20-40 cm soil layer. Maize yield was the highest under STS and the lowest under RTS. Particularly, ROC (<0.053 mm) in the 0-20 cm soil layer and MBC in the 20-40 cm soil layer (>2 mm, 2-0.25 mm) remarkably affected maize yield. Overall, this study demonstrates that the STS treatment can provide an optimal pathway for achieving both high SOC sequestration and maize yield. Future research should further elucidate the coupling mechanism between microbial functional redundancy and carbon turnover dynamics under long-term tillage practices to provide theoretical support for precision agricultural management.

News (Medical) associated with Sodium Thiosulfate

31 Mar 2026

·www.globenewswire.com

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company’s common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). All ISOs have an exercise price of $5.77 per share, which is equal to the closing price of the Company’s common shares on The Nasdaq Capital Market on March 30, 2026, and a term of ten years from the date of grant. One-third of the shares underlying each ISO vest on the one-year anniversary of the grant date and continue to vest monthly thereafter over 24 months, subject to each employee’s continued employment with Company as of each such vesting date. The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an ISO agreement covering the grant. About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI® is now commercially available in the U.K. and Germany. PEDMARK® has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI® has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com and follow on LinkedIn. Forward Looking Statements Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about the Company’s business strategy, timeline and other goals, plans and prospects, including the Company’s commercialization plans respecting PEDMARK®/PEDMARQSI®, the market opportunity for and market impact of PEDMARK®/ PEDMARQSI®, its potential impact on patients and anticipated benefits associated with its use, future commercial and regulatory milestone and royalty payments from Norgine, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company’s ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2025. Fennec disclaims any obligation to update these forward-looking statements except as required by law. For a more detailed discussion of related risk factors, please refer to the Company’s public filings available at www.sec.gov and www.sedar.com. PEDMARK®, PEDMARQSI® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc. ©2025 Fennec Pharmaceuticals Inc. All rights reserved For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate and Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Orphan DrugLicense out/inDrug Approval

31 Mar 2026

·www.biospace.com

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 31, 2026

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company’s common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). All ISOs have an exercise price of $5.77 per share, which is equal to the closing price of the Company’s common shares on The Nasdaq Capital Market on March 30, 2026, and a term of ten years from the date of grant. One-third of the shares underlying each ISO vest on the one-year anniversary of the grant date and continue to vest monthly thereafter over 24 months, subject to each employee’s continued employment with Company as of each such vesting date. The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an ISO agreement covering the grant. About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK ® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK ® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI ® . In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in Europe, U.K., Australia and New Zealand. PEDMARQSI ® is now commercially available in the U.K. and Germany. PEDMARK ® has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI ® has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. For more information, please visit and follow on LinkedIn. Forward Looking Statements Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about the Company’s business strategy, timeline and other goals, plans and prospects, including the Company’s commercialization plans respecting PEDMARK ® /PEDMARQSI ® , the market opportunity for and market impact of PEDMARK ® / PEDMARQSI ® , its potential impact on patients and anticipated benefits associated with its use, future commercial and regulatory milestone and royalty payments from Norgine, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company’s ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2025. Fennec disclaims any obligation to update these forward-looking statements except as required by law. For a more detailed discussion of related risk factors, please refer to the Company’s public filings available at and PEDMARK ® , PEDMARQSI ® and Fennec ® are registered trademarks of Fennec Pharmaceuticals Inc. ©2025 Fennec Pharmaceuticals Inc. All rights reserved For further information, please contact: Investors: Robert Andrade Chief Financial Officer Fennec Pharmaceuticals Inc. +1 919-246-5299 Corporate and Media: Lindsay Rocco Elixir Health Public Relations +1 862-596-1304 lrocco@elixirhealthpr.com

Drug ApprovalLicense out/inOrphan Drug

26 Mar 2026

·www.prnewswire.com

Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children

PEDMARQSI® (sodium thiosulfate solution for infusion) becomes the first and only treatment authorised in Switzerland for the prevention of cisplatin-induced ototoxicity (hearing loss) in patients aged 1 month to <18 years of age with localised, non-metastatic, solid tumours.1 Swissmedic's decision provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy. The data from 2 open-label, randomised Phase 3 trials, SIOPEL 6 (pivotal)2 and the Clinical Oncology Group [COG] ACCL04313, resulted in an approximately 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin and sodium thiosulfate vs. those treated with cisplatin alone. AMSTERDAM, March 26, 2026 /PRNewswire/ -- Norgine B.V., a leading European specialty pharmaceutical company today announced that Swissmedic has granted marketing authorisation for PEDMARQSI® (sodium thiosulfate solution for infusion) indicated for the prevention of cisplatin induced ototoxicity (hearing loss) in patients aged 1 month to <18 years with localised, non-metastatic solid tumours. PEDMARQSI® is the first and only pharmacological treatment specifically developed to prevent cisplatin induced hearing loss in children. While cisplatin remains a cornerstone of paediatric cancer treatment, it is associated with a high risk of irreversible, bilateral hearing loss that can begin with the first dose and progress over time. Hearing loss can have a profound and lasting impact on a child's speech and language acquisition, education, psychosocial development and overall quality of life. Rüdiger Merkel, General Manager, DACH, Norgine, said: "The Swissmedic approval of PEDMARQSI® represents an important milestone for children, families and healthcare professionals in Switzerland, where no approved pharmacological option has previously been available to help prevent this complication of cisplatin treatment. Hearing loss can have a lifelong impact on young patients, and this approval supports access to a treatment developed specifically to address this unmet medical need." The Swissmedic approval is based on clinical evidence from two open label, randomised Phase 3 trials . Across these studies, treatment with sodium thiosulfate administered alongside cisplatin resulted in approximately a 50% reduction in the occurrence of cisplatin-induced ototoxicity compared with cisplatin alone, while maintaining the efficacy of chemotherapy.2,3 PEDMARQSI® has previously been granted paediatric use marketing authorisation (PUMA) by the European Medicines Agency (EMA) in May 2023 in the European Union and a national marketing authorisation in the United Kingdom.4,5 Together, these approvals reflect Norgine's ability to successfully navigate diverse European regulatory pathways for rare and specialist medicines. About PEDMARQSI® PEDMARQSI® is a novel formulation of anhydrous sodium thiosulfate, specifically developed and manufactured for the prevention of cisplatin induced hearing loss in patients aged 1 month to <18 years with localised, nonmetastatic solid tumours. It is the first and only preventative treatment developed for cisplatin induced ototoxicity in this patient population.1 Marketing authorisations for PEDMARQSI® were based on safety and efficacy data from two open label, randomised Phase III trials: SIOPEL 6 (pivotal) and Clinical Oncology Group (COG) ACCL0431.2,3 Across these studies, sodium thiosulfate significantly reduced the risk of hearing loss associated with cisplatin chemotherapy. The trials demonstrated a favourable tolerability profile, with nausea and vomiting being the most commonly reported adverse events, and infection, anaemia and neutropenia being the most common grade 3–4 adverse events.2,3 About Norgine Norgine is a mid-sized EU-based pharmaceutical company with 1,500 employees, generating approximately $650 million in annual sales. At Norgine, innovation drives our mission to deliver medicines that change lives. From common conditions like constipation to rare and severe diseases such as childhood cancer, we target unmet medical needs because we believe that every scientific breakthrough deserves to reach patients in need. We use our innovative development, commercialisation and manufacturing capabilities as well as strategic partnerships to navigate complex pathways. Combined with our extensive history and deep regional expertise, this approach allows us to accelerate and expand the reach of life-changing medicines across Europe, Australia, and New Zealand. We are guided by the trust that healthcare professionals and patients place in us and remain committed to delivering innovation that transforms lives, one patient at a time. References: PEDMARQSI Product Information. Available at: . Accessed March 2026 Brock PR, et al. N Engl J Med 2018; 378(25): 2376–2385 Freyer DR, et al. Lancet Oncol 2017; 18(1): 63–74 EMA. PEDMARQSI. Available at: . Accessed March 2026. MHRA. PEDMARSQI. Available at: . Accessed March 2026. Logo - 21% more press release views with Request a Demo

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Sodium Thiosulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D01091	Sodium Thiosulfate	V03AB06	DB09499

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hearing Loss	Switzerland	Norgine BV	26 Mar 2026
Ototoxicity	United States	Fennec Pharmaceuticals, Inc.	20 Sep 2022
Disinfectants	Japan	Kenei Pharmaceutical Co Ltd.	12 Nov 2013
Cyanide poisoning	Australia	Pfizer Australia Pty Ltd.	30 Aug 2007
Poisoning	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	11 May 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Calciphylaxis	Phase 3	United States	Hope Pharmaceuticals, Inc.	24 May 2017
Calciphylaxis	Phase 3	Canada	Hope Pharmaceuticals, Inc.	24 May 2017
Calciphylaxis	Phase 3	United Kingdom	Hope Pharmaceuticals, Inc.	24 May 2017
Eye Diseases	Phase 2	Belgium	Byondis BV	10 Jan 2022
Eye Diseases	Phase 2	France	Byondis BV	10 Jan 2022
Eye Diseases	Phase 2	Spain	Byondis BV	10 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04541355 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Ototoxicity \| Nasopharyngeal Carcinoma ... View more	16	Hearing Handicap Inventory for Adults - Screening+Sodium Thiosulfate+cisplatin	wfhwwfuzjn = dumpmdundq pcpzvykxqi (djugaxugzj, aukmeoowtd - lllqejizsv) View more	-	28 Jun 2024
NCT03267277 (CTgov)	Phase 2/3	Idiopathic Inflammatory Myopathies \| Dermatomyositis \| Calcinosis	15	Sodium Thiosulfate	qzhrmwftdv(xnoaibnmjo) = xfsjmelbra iqnezxozul (rconqpcqhe, 0.89) View more	-	26 Feb 2024
EMA Manual	Not Applicable	Ototoxicity	104	cisplatin (with different types of cancer)	jhboaacudf(wxoxjiuoqp) = The risk of having hearing loss was statistically significantly lower in the CIS+STS arm compared with the CIS Alone arm, corresponding to a clinically meaningful 48% lower risk after STS treatment. tifscaqucw (jwzhjrdsmk ) View more	Positive	02 Jun 2023
				sodium thiosulfate+cisplatin (with different types of cancer)
EMA Manual	Not Applicable	Ototoxicity	109	cisplatin (with hepatoblastoma)	auiqmlhfie(ppmjwhkdnz) = izqbiwcgxo ogwvavrgzx (shwelffndg ) View more	Positive	02 Jun 2023
				sodium thiosulfate+cisplatin (with hepatoblastoma)	auiqmlhfie(ppmjwhkdnz) = orkmqzuvjn ogwvavrgzx (shwelffndg ) View more
NCT04262336 (ASCO 12023 \| ASCO 22023) Manual	Phase 1	Ototoxicity	19	DB-020	xeupxzvmwy(anjpitaghb) = Ear pain (15/19 subjects, 78.9%) and tinnitus (8/19 subjects, 42.1%) were common. Ear pain was more common in DB-020 treated ears, and tinnitus was more common in placebo treated ears. lkjtxvvckh (sdgvbgsfre ) View more	Positive	26 May 2023
				Placebo
NCT04262336 (Corporate Publications) Manual	Phase 1	Hearing Loss	19	DB-020	pjunljywlt(wzfwbuotkg) = pzynbanaqo tewumhrjex (snnpxbdmgo )	Positive	28 Jun 2022
				Placebo	pjunljywlt(wzfwbuotkg) = nxnzewpdja tewumhrjex (snnpxbdmgo )
ERA2022	Not Applicable	Calciphylaxis Maintenance	-	Optimized Sodium Thiosulfate Therapy	jidovubzql(jnwsqxchjl) = most adverse events appeared in the course of increasing the STS dose and would be relieved when we stopped adding it or decreased to the day-before dose enzeexfzfq (knpammjrjz )	Positive	03 May 2022
NCT03639779 (CTgov)	Phase 4	Calcinosis cutis	5	Sodium Thiosulfate (Sodium Thiosulfate)	zghiwrfrlr(fuhybdoxpb) = jkpicxefco zfqoagrpct (rrsothrljm, ydzowlgasy - jgvewlfymj) View more	-	01 Jul 2021
				Saline Solution (Saline Solution)	zghiwrfrlr(fuhybdoxpb) = mptpqbgzbh zfqoagrpct (rrsothrljm, tsvbucvkhe - zbzaobakkq) View more
NCT02092298 (CTgov)	Phase 2	Metastatic Gastric Carcinoma	21	Mitomycin C+Sodium Thiosulfate+Cisplatin	emorugqqke(xdtshqocab) = qputrlvekw xdcbyvoqos (djxfgzgfvi, 18.3) View more	-	15 Jun 2021
EULAR2020	Not Applicable	Skin Ulcer	9	Topical Sodium Thiosulfate (TST)	bkwmmbxulb(hcpcjndwwz) = wdwqhiqiwa zptmiwcdxe (pkvmbjcnku, 8.25)	Positive	03 Jun 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis